Quest Diagnostics Inc.
DGXQuest Diagnostics Inc. (DGX) is a leading provider of diagnostic testing, information, and services that help clinicians, health plans, and laboratories improve patient care. Founded in 1967 and headquartered in Irving, Texas, the company offers a broad range of laboratory testing services, including clinical chemistry, molecular diagnostics, and pathology, supporting healthcare providers with insights to inform treatment decisions.
Dividend History
Investors can expect a dividend payout of $0.86 per share, scheduled to be distributed in 4 days on July 22, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 22, 2026 | $0.86 | 2026-07-08 | 2026-07-08 |
| April 20, 2026 | $0.86 | 2026-04-06 | 2026-04-06 |
| January 28, 2026 | $0.80 | 2026-01-13 | 2026-01-13 |
| October 20, 2025 | $0.80 | 2025-10-03 | 2025-10-03 |
| July 21, 2025 | $0.80 | 2025-07-07 | 2025-07-07 |
Dividends Summary
- Consistent Payer: Quest Diagnostics Inc. has rewarded shareholders with 90 dividend payments over the past 22 years.
- Total Returned Value: Investors who held DGX shares during this period received a total of $34.09 per share in dividend income.
- Latest Payout: The most recent dividend of $0.86/share was paid 89 days ago, on April 20, 2026.
- Yield & Schedule: DGX currently pays dividends quarterly with an annual yield of 1.58%.
- Dividend Growth: Since 2004, the dividend payout has grown by 473.3%, from $0.15 to $0.86.
- Dividend Reliability: DGX has maintained or increased its dividend for 85 consecutive payments.
Company News
A Canadian health coalition has called on Ontario's Health Minister to halt Quest Diagnostics' transfer of laboratory testing services from Ontario hospitals to U.S.-based facilities. The coalition argues that the transfers, which began in April 2026, compromise patient privacy, reduce hospital efficiency, delay results, and divert healthcare fun...
Quest Diagnostics announced a quarterly cash dividend of $0.86 per share, payable on July 22, 2026 to shareholders of record as of July 8, 2026. The diagnostic information services leader serves half of U.S. physicians and hospitals and one in three American adults annually.
The global HPV testing and Pap test market is projected to grow from USD 3.7 billion in 2025 to USD 6.5 billion by 2034, driven by rising cervical cancer prevalence, government screening initiatives, technological advancements, and the introduction of self-sampling tests. North America leads the market with 40.5% share, while Asia-Pacific emerges...
The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fu...
The global genomics services market is expected to grow from USD 7.94 billion in 2025 to USD 25.18 billion by 2035, with a CAGR of 11.8%. Growth is driven by increasing genetic disorder prevalence, government-funded precision medicine initiatives, and rising adoption of NGS-based diagnostics. The U.S. market alone is projected to reach USD 10.04 ...
